The effect of interleukin-10 gene promoter polymorphisms on early-onset coronary artery disease
Küçük Resim Yok
Tarih
2011
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu çalışmada, koroner kalp hastalığı (KKH) ve interlökin-10 (IL-10) -1082 G/A ve -592C/A promotor polimorfizmleri arasındaki ilişkinin değerlendirilmesi hedeflenmiştir. Yöntemler: Enine-kesitli gözlemsel olarak tasarlanan bu çalışmada, koroner kalp hastalığı tanısı alan 86 hasta (ortalama yaş 43.36±4.930 yıl) KKH ve 88 sağlıklı kontrolde (ortalama yaş 47.07±8.135 yıl) interlökin-10 (IL-10) -1082 G/A ve -592C/A promotor polimorfizmleri RFLP ve jel elektroforezi yöntemi ile çalışılmıştır. KKH ve kontrol grubu arasındaki polimorfizmlerin genotip dağılımları Ki-kare analizi ile değerlendirilmiştir. Bulgular: Hasta (GG:%38.3; GA:%51.1; AA:%10.6) ve kontrol (GG:%43.1; GC:%43.1; CC:%13.8) (p=0.57) grupları arasında IL-10, -1082 G/A polimorfizmi genotip dağılımları arasında bir fark saptanmadı. Aynı polimorfizm allel sıklığı açısından değerlendirildiğinde A alleli sıklığı hasta grubunda %36.6, kontrol grubunda %35.3 olması nedeniyle belirgin bir fark görülmedi. IL-10 -592C/A polimorfizmi hem allel, hem de genotip frekansları değerlendirildiğinde hasta ve kontrol grupları arasında istatistiksel olarak anlamlı bir farka rastlanmadı. Polimorfizmlere özgü allel ve genotip frekansları ve haplotipler ile anjiyografik ve klinik bulgular arasında istatistiksel olarak anlamlı bir fark bulunmadı. Genç KKH olan (<45 yaş), hastaların yaş uyumlu kontrolleri ile yapılan karşılaştırmada IL-10 -592C/A polimorfizmi allel sıklığı (OR=2.00 % GA=0.9434-4.2579) açısından istatistiksel olarak anlamlı bir fark saptanmıştır. Sonuç: Bu çalışma IL-10-592 C/A polimorfizminin genç KKH’na yatkınlıkta bir rolünün olabileceğini düşündürtmektedir.
Objective: We assessed the association between interleukin-10 (IL-10) -1082G/A and -592C/A polymorphisms, and coronary heart disease (CHD). Methods: A cross-sectional, observational study included 86 patients (mean age 43.36±4.930 years) diagnosed to have CHD and 88 healthy controls (mean age 47.07±8.135 years). IL-10 -1082G/A and -592C/A polymorphisms were analyzed using restriction fragment length polymorphism (RFLP) and agarose gel electrophoresis methods in both patient and control groups. Genotype distributions of the polymorphisms between CHD patients and controls were assessed by Chi-square analysis. Results: The genotype distribution of the -1082 G/A polymorphism was not different in premature CHD patients (GG: 38.3%; GA: 51.1%; AA: 10.6%) and controls (GG: 43.1%; GC: 43.1%; CC: 13.8%) (p=0.57). The prevalence of the A allele at -1082G/A polymorphism was 36.6% in patients and 35.3% in controls. Both allele and genotype frequencies of -592C/A polymorphism did not also differ significantly between patients with CHD and controls. We did not observe relationships between polymorphism-specific haplotypes and adverse angiographic and clinical outcomes. We have observed a significant difference of IL-10 -592C/A allelic frequency (OR=2.00 95% CI=0.9434-4.2579) between the younger CHD patients (<45 years, Group 2) and matched controls. Conclusion: Our study suggests that IL-10-592C/A polymorphism may play a role in susceptibility to CHD in younger patients.
Objective: We assessed the association between interleukin-10 (IL-10) -1082G/A and -592C/A polymorphisms, and coronary heart disease (CHD). Methods: A cross-sectional, observational study included 86 patients (mean age 43.36±4.930 years) diagnosed to have CHD and 88 healthy controls (mean age 47.07±8.135 years). IL-10 -1082G/A and -592C/A polymorphisms were analyzed using restriction fragment length polymorphism (RFLP) and agarose gel electrophoresis methods in both patient and control groups. Genotype distributions of the polymorphisms between CHD patients and controls were assessed by Chi-square analysis. Results: The genotype distribution of the -1082 G/A polymorphism was not different in premature CHD patients (GG: 38.3%; GA: 51.1%; AA: 10.6%) and controls (GG: 43.1%; GC: 43.1%; CC: 13.8%) (p=0.57). The prevalence of the A allele at -1082G/A polymorphism was 36.6% in patients and 35.3% in controls. Both allele and genotype frequencies of -592C/A polymorphism did not also differ significantly between patients with CHD and controls. We did not observe relationships between polymorphism-specific haplotypes and adverse angiographic and clinical outcomes. We have observed a significant difference of IL-10 -592C/A allelic frequency (OR=2.00 95% CI=0.9434-4.2579) between the younger CHD patients (<45 years, Group 2) and matched controls. Conclusion: Our study suggests that IL-10-592C/A polymorphism may play a role in susceptibility to CHD in younger patients.
Açıklama
Anahtar Kelimeler
Kalp ve Kalp Damar Sistemi
Kaynak
Anadolu Kardiyoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
11
Sayı
4
